A global Phase 3 clinical trial (VIKTORIA‐1, NCT05501886) is currently evaluating gedatolisib in combination with fulvestrant, with and without palbociclib, in patients with HR+/HER2− advanced breast cancer. This evidence concerns the gene HR and breast carcinoma.